SIRT2 deacetylates and decreases the expression of FOXM1 in colon cancer

New FOXM1‐specific inhibitors with the potential to be used for therapeutic purposes are under extensive research. We hypothesized that deacetylation of FOXM1 would decrease protein expression, thus providing novel therapeutic management of colon cancers. Immunostaining was used to determine FOXM1 a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of biochemical and molecular toxicology 2024-11, Vol.38 (11), p.e70018-n/a
Hauptverfasser: Yildiz, Baris, Demirel, Ramazan, Staudacher, Jonas J., Beseren, Hatice, Yildiz, Gulden, Akpinar, Ali Emre, Park, Seong‐Hoon, Ozden, Ozkan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page n/a
container_issue 11
container_start_page e70018
container_title Journal of biochemical and molecular toxicology
container_volume 38
creator Yildiz, Baris
Demirel, Ramazan
Staudacher, Jonas J.
Beseren, Hatice
Yildiz, Gulden
Akpinar, Ali Emre
Park, Seong‐Hoon
Ozden, Ozkan
description New FOXM1‐specific inhibitors with the potential to be used for therapeutic purposes are under extensive research. We hypothesized that deacetylation of FOXM1 would decrease protein expression, thus providing novel therapeutic management of colon cancers. Immunostaining was used to determine FOXM1 and SIRT2 expressions in human colon cancer tissue microarrays (n = 90) from Stage I to Stage IV. SIRT2‐FOXM1 interaction was evaluated in colon cancer cells using immunoprecipitation. Deacetylation of FOXM1 via SIRT2 was determined using in vitro deacetylation assays. FOXM1 could be hyper‐acetylated when p300 and pCAF histone acetyltransferases were administered alongside deacetylase inhibitors. We detected that SIRT2 and FOXM1 physically interacted, and SIRT2 deacetylated FOXM1 in vitro. SIRT2 overexpression led to a significant decrease while knockdown of SIRT2 increased the FOXM1 expression in HCT116 human colon carcinoma cells. In the analysis of 90 human colorectal cancer samples, high SIRT2 expression was observed in about 49% of colorectal cancer, intermediate in 29%, and low or no staining in 22%. Strong SIRT2 expression was found to be negatively associated with the FOXM1 staining in our clinical cohort. This study reveals a molecular interaction and association between SIRT2 and FOXM1 expression in colon cancer cell lines and human colon cancer samples, and suggests that targeting SIRT2 activity using small molecule modulators may be a promising therapeutic approach for colorectal cancer. SIRT2‐FOXM1 interaction in colon cancer. SIRT2 and FOXM1 physically interacted and SIRT2 deacetylated FOXM1 in vitro. Strong SIRT2 expression was negatively associated with FOXM1 staining in a human colon carcinoma tissue microarray. Resveratrol, berberine, and quercetin reduced FOXM1 expression in colon cancer cells. Highlights Upregulation of FOXM1 may be an early molecular signal required for cancer SIRT2 and FOXM1 physically interacted, and SIRT2 deacetylated FOXM1 in vitro Strong SIRT2 expression was negatively associated with the FOXM1 staining in the TMA Resveratrol, berberine and quercetin decreased FOXM1 expression in colorectal cancer cells
doi_str_mv 10.1002/jbt.70018
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3118305886</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3118305886</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2788-ad354f4aeedd3b677cd2e064e11b7c89c6cc6dc60b3dc7b56c7b8dae92bb18a63</originalsourceid><addsrcrecordid>eNp10E9LwzAYBvAgipvTg19ACl700C1JmzQ96nBuogx0greQJm-xo2tn0qL79mbr9CB4yZ-XHw8vD0LnBA8JxnS0zJphgjERB6hPcJqGOObkcPdmIecJ7qET55YYY5Ym7Bj1ojSmLGZxH01fZs8LGhhQGppNqRpwgaqMH2gLyvlf8w4BfK0tOFfUVVDnwWT-9kSCogp0XfqJVpUGe4qOclU6ONvfA_Q6uVuMp-Hj_H42vnkMNU2ECJWJWJzHCsCYKONJog0FzGMgJEu0SDXXmhvNcRYZnWSM-0MYBSnNMiIUjwboqstd2_qjBdfIVeE0lKWqoG6djAgREWZCbOnlH7qsW1v57byiXAhCI-LVdae0rZ2zkMu1LVbKbiTBcluv9PXKXb3eXuwT22wF5lf-9OnBqAOfRQmb_5Pkw-2ii_wGSguCyw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3126881231</pqid></control><display><type>article</type><title>SIRT2 deacetylates and decreases the expression of FOXM1 in colon cancer</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Yildiz, Baris ; Demirel, Ramazan ; Staudacher, Jonas J. ; Beseren, Hatice ; Yildiz, Gulden ; Akpinar, Ali Emre ; Park, Seong‐Hoon ; Ozden, Ozkan</creator><creatorcontrib>Yildiz, Baris ; Demirel, Ramazan ; Staudacher, Jonas J. ; Beseren, Hatice ; Yildiz, Gulden ; Akpinar, Ali Emre ; Park, Seong‐Hoon ; Ozden, Ozkan</creatorcontrib><description>New FOXM1‐specific inhibitors with the potential to be used for therapeutic purposes are under extensive research. We hypothesized that deacetylation of FOXM1 would decrease protein expression, thus providing novel therapeutic management of colon cancers. Immunostaining was used to determine FOXM1 and SIRT2 expressions in human colon cancer tissue microarrays (n = 90) from Stage I to Stage IV. SIRT2‐FOXM1 interaction was evaluated in colon cancer cells using immunoprecipitation. Deacetylation of FOXM1 via SIRT2 was determined using in vitro deacetylation assays. FOXM1 could be hyper‐acetylated when p300 and pCAF histone acetyltransferases were administered alongside deacetylase inhibitors. We detected that SIRT2 and FOXM1 physically interacted, and SIRT2 deacetylated FOXM1 in vitro. SIRT2 overexpression led to a significant decrease while knockdown of SIRT2 increased the FOXM1 expression in HCT116 human colon carcinoma cells. In the analysis of 90 human colorectal cancer samples, high SIRT2 expression was observed in about 49% of colorectal cancer, intermediate in 29%, and low or no staining in 22%. Strong SIRT2 expression was found to be negatively associated with the FOXM1 staining in our clinical cohort. This study reveals a molecular interaction and association between SIRT2 and FOXM1 expression in colon cancer cell lines and human colon cancer samples, and suggests that targeting SIRT2 activity using small molecule modulators may be a promising therapeutic approach for colorectal cancer. SIRT2‐FOXM1 interaction in colon cancer. SIRT2 and FOXM1 physically interacted and SIRT2 deacetylated FOXM1 in vitro. Strong SIRT2 expression was negatively associated with FOXM1 staining in a human colon carcinoma tissue microarray. Resveratrol, berberine, and quercetin reduced FOXM1 expression in colon cancer cells. Highlights Upregulation of FOXM1 may be an early molecular signal required for cancer SIRT2 and FOXM1 physically interacted, and SIRT2 deacetylated FOXM1 in vitro Strong SIRT2 expression was negatively associated with the FOXM1 staining in the TMA Resveratrol, berberine and quercetin decreased FOXM1 expression in colorectal cancer cells</description><identifier>ISSN: 1095-6670</identifier><identifier>ISSN: 1099-0461</identifier><identifier>EISSN: 1099-0461</identifier><identifier>DOI: 10.1002/jbt.70018</identifier><identifier>PMID: 39425454</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Acetylation ; Berberine ; Colon ; Colon cancer ; Colonic Neoplasms - genetics ; Colonic Neoplasms - metabolism ; Colonic Neoplasms - pathology ; Colorectal cancer ; Colorectal carcinoma ; CRC ; Deacetylation ; Disease management ; Female ; Forkhead Box Protein M1 - genetics ; Forkhead Box Protein M1 - metabolism ; FOXM1 ; Gene Expression Regulation, Neoplastic - drug effects ; HCT116 Cells ; Histones ; Humans ; Immunomodulation ; Immunoprecipitation ; Inhibitors ; Male ; Molecular interactions ; posttranslational regulation ; Quercetin ; Resveratrol ; SirReal2 ; sirtuin ; Sirtuin 2 - genetics ; Sirtuin 2 - metabolism ; Staining ; Therapeutic applications ; Tumor cell lines</subject><ispartof>Journal of biochemical and molecular toxicology, 2024-11, Vol.38 (11), p.e70018-n/a</ispartof><rights>2024 The Author(s). published by Wiley Periodicals LLC.</rights><rights>2024 The Author(s). Journal of Biochemical and Molecular Toxicology published by Wiley Periodicals LLC.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2788-ad354f4aeedd3b677cd2e064e11b7c89c6cc6dc60b3dc7b56c7b8dae92bb18a63</cites><orcidid>0000-0002-9467-3761</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjbt.70018$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjbt.70018$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39425454$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yildiz, Baris</creatorcontrib><creatorcontrib>Demirel, Ramazan</creatorcontrib><creatorcontrib>Staudacher, Jonas J.</creatorcontrib><creatorcontrib>Beseren, Hatice</creatorcontrib><creatorcontrib>Yildiz, Gulden</creatorcontrib><creatorcontrib>Akpinar, Ali Emre</creatorcontrib><creatorcontrib>Park, Seong‐Hoon</creatorcontrib><creatorcontrib>Ozden, Ozkan</creatorcontrib><title>SIRT2 deacetylates and decreases the expression of FOXM1 in colon cancer</title><title>Journal of biochemical and molecular toxicology</title><addtitle>J Biochem Mol Toxicol</addtitle><description>New FOXM1‐specific inhibitors with the potential to be used for therapeutic purposes are under extensive research. We hypothesized that deacetylation of FOXM1 would decrease protein expression, thus providing novel therapeutic management of colon cancers. Immunostaining was used to determine FOXM1 and SIRT2 expressions in human colon cancer tissue microarrays (n = 90) from Stage I to Stage IV. SIRT2‐FOXM1 interaction was evaluated in colon cancer cells using immunoprecipitation. Deacetylation of FOXM1 via SIRT2 was determined using in vitro deacetylation assays. FOXM1 could be hyper‐acetylated when p300 and pCAF histone acetyltransferases were administered alongside deacetylase inhibitors. We detected that SIRT2 and FOXM1 physically interacted, and SIRT2 deacetylated FOXM1 in vitro. SIRT2 overexpression led to a significant decrease while knockdown of SIRT2 increased the FOXM1 expression in HCT116 human colon carcinoma cells. In the analysis of 90 human colorectal cancer samples, high SIRT2 expression was observed in about 49% of colorectal cancer, intermediate in 29%, and low or no staining in 22%. Strong SIRT2 expression was found to be negatively associated with the FOXM1 staining in our clinical cohort. This study reveals a molecular interaction and association between SIRT2 and FOXM1 expression in colon cancer cell lines and human colon cancer samples, and suggests that targeting SIRT2 activity using small molecule modulators may be a promising therapeutic approach for colorectal cancer. SIRT2‐FOXM1 interaction in colon cancer. SIRT2 and FOXM1 physically interacted and SIRT2 deacetylated FOXM1 in vitro. Strong SIRT2 expression was negatively associated with FOXM1 staining in a human colon carcinoma tissue microarray. Resveratrol, berberine, and quercetin reduced FOXM1 expression in colon cancer cells. Highlights Upregulation of FOXM1 may be an early molecular signal required for cancer SIRT2 and FOXM1 physically interacted, and SIRT2 deacetylated FOXM1 in vitro Strong SIRT2 expression was negatively associated with the FOXM1 staining in the TMA Resveratrol, berberine and quercetin decreased FOXM1 expression in colorectal cancer cells</description><subject>Acetylation</subject><subject>Berberine</subject><subject>Colon</subject><subject>Colon cancer</subject><subject>Colonic Neoplasms - genetics</subject><subject>Colonic Neoplasms - metabolism</subject><subject>Colonic Neoplasms - pathology</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>CRC</subject><subject>Deacetylation</subject><subject>Disease management</subject><subject>Female</subject><subject>Forkhead Box Protein M1 - genetics</subject><subject>Forkhead Box Protein M1 - metabolism</subject><subject>FOXM1</subject><subject>Gene Expression Regulation, Neoplastic - drug effects</subject><subject>HCT116 Cells</subject><subject>Histones</subject><subject>Humans</subject><subject>Immunomodulation</subject><subject>Immunoprecipitation</subject><subject>Inhibitors</subject><subject>Male</subject><subject>Molecular interactions</subject><subject>posttranslational regulation</subject><subject>Quercetin</subject><subject>Resveratrol</subject><subject>SirReal2</subject><subject>sirtuin</subject><subject>Sirtuin 2 - genetics</subject><subject>Sirtuin 2 - metabolism</subject><subject>Staining</subject><subject>Therapeutic applications</subject><subject>Tumor cell lines</subject><issn>1095-6670</issn><issn>1099-0461</issn><issn>1099-0461</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp10E9LwzAYBvAgipvTg19ACl700C1JmzQ96nBuogx0greQJm-xo2tn0qL79mbr9CB4yZ-XHw8vD0LnBA8JxnS0zJphgjERB6hPcJqGOObkcPdmIecJ7qET55YYY5Ym7Bj1ojSmLGZxH01fZs8LGhhQGppNqRpwgaqMH2gLyvlf8w4BfK0tOFfUVVDnwWT-9kSCogp0XfqJVpUGe4qOclU6ONvfA_Q6uVuMp-Hj_H42vnkMNU2ECJWJWJzHCsCYKONJog0FzGMgJEu0SDXXmhvNcRYZnWSM-0MYBSnNMiIUjwboqstd2_qjBdfIVeE0lKWqoG6djAgREWZCbOnlH7qsW1v57byiXAhCI-LVdae0rZ2zkMu1LVbKbiTBcluv9PXKXb3eXuwT22wF5lf-9OnBqAOfRQmb_5Pkw-2ii_wGSguCyw</recordid><startdate>202411</startdate><enddate>202411</enddate><creator>Yildiz, Baris</creator><creator>Demirel, Ramazan</creator><creator>Staudacher, Jonas J.</creator><creator>Beseren, Hatice</creator><creator>Yildiz, Gulden</creator><creator>Akpinar, Ali Emre</creator><creator>Park, Seong‐Hoon</creator><creator>Ozden, Ozkan</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9467-3761</orcidid></search><sort><creationdate>202411</creationdate><title>SIRT2 deacetylates and decreases the expression of FOXM1 in colon cancer</title><author>Yildiz, Baris ; Demirel, Ramazan ; Staudacher, Jonas J. ; Beseren, Hatice ; Yildiz, Gulden ; Akpinar, Ali Emre ; Park, Seong‐Hoon ; Ozden, Ozkan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2788-ad354f4aeedd3b677cd2e064e11b7c89c6cc6dc60b3dc7b56c7b8dae92bb18a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acetylation</topic><topic>Berberine</topic><topic>Colon</topic><topic>Colon cancer</topic><topic>Colonic Neoplasms - genetics</topic><topic>Colonic Neoplasms - metabolism</topic><topic>Colonic Neoplasms - pathology</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>CRC</topic><topic>Deacetylation</topic><topic>Disease management</topic><topic>Female</topic><topic>Forkhead Box Protein M1 - genetics</topic><topic>Forkhead Box Protein M1 - metabolism</topic><topic>FOXM1</topic><topic>Gene Expression Regulation, Neoplastic - drug effects</topic><topic>HCT116 Cells</topic><topic>Histones</topic><topic>Humans</topic><topic>Immunomodulation</topic><topic>Immunoprecipitation</topic><topic>Inhibitors</topic><topic>Male</topic><topic>Molecular interactions</topic><topic>posttranslational regulation</topic><topic>Quercetin</topic><topic>Resveratrol</topic><topic>SirReal2</topic><topic>sirtuin</topic><topic>Sirtuin 2 - genetics</topic><topic>Sirtuin 2 - metabolism</topic><topic>Staining</topic><topic>Therapeutic applications</topic><topic>Tumor cell lines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yildiz, Baris</creatorcontrib><creatorcontrib>Demirel, Ramazan</creatorcontrib><creatorcontrib>Staudacher, Jonas J.</creatorcontrib><creatorcontrib>Beseren, Hatice</creatorcontrib><creatorcontrib>Yildiz, Gulden</creatorcontrib><creatorcontrib>Akpinar, Ali Emre</creatorcontrib><creatorcontrib>Park, Seong‐Hoon</creatorcontrib><creatorcontrib>Ozden, Ozkan</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of biochemical and molecular toxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yildiz, Baris</au><au>Demirel, Ramazan</au><au>Staudacher, Jonas J.</au><au>Beseren, Hatice</au><au>Yildiz, Gulden</au><au>Akpinar, Ali Emre</au><au>Park, Seong‐Hoon</au><au>Ozden, Ozkan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SIRT2 deacetylates and decreases the expression of FOXM1 in colon cancer</atitle><jtitle>Journal of biochemical and molecular toxicology</jtitle><addtitle>J Biochem Mol Toxicol</addtitle><date>2024-11</date><risdate>2024</risdate><volume>38</volume><issue>11</issue><spage>e70018</spage><epage>n/a</epage><pages>e70018-n/a</pages><issn>1095-6670</issn><issn>1099-0461</issn><eissn>1099-0461</eissn><abstract>New FOXM1‐specific inhibitors with the potential to be used for therapeutic purposes are under extensive research. We hypothesized that deacetylation of FOXM1 would decrease protein expression, thus providing novel therapeutic management of colon cancers. Immunostaining was used to determine FOXM1 and SIRT2 expressions in human colon cancer tissue microarrays (n = 90) from Stage I to Stage IV. SIRT2‐FOXM1 interaction was evaluated in colon cancer cells using immunoprecipitation. Deacetylation of FOXM1 via SIRT2 was determined using in vitro deacetylation assays. FOXM1 could be hyper‐acetylated when p300 and pCAF histone acetyltransferases were administered alongside deacetylase inhibitors. We detected that SIRT2 and FOXM1 physically interacted, and SIRT2 deacetylated FOXM1 in vitro. SIRT2 overexpression led to a significant decrease while knockdown of SIRT2 increased the FOXM1 expression in HCT116 human colon carcinoma cells. In the analysis of 90 human colorectal cancer samples, high SIRT2 expression was observed in about 49% of colorectal cancer, intermediate in 29%, and low or no staining in 22%. Strong SIRT2 expression was found to be negatively associated with the FOXM1 staining in our clinical cohort. This study reveals a molecular interaction and association between SIRT2 and FOXM1 expression in colon cancer cell lines and human colon cancer samples, and suggests that targeting SIRT2 activity using small molecule modulators may be a promising therapeutic approach for colorectal cancer. SIRT2‐FOXM1 interaction in colon cancer. SIRT2 and FOXM1 physically interacted and SIRT2 deacetylated FOXM1 in vitro. Strong SIRT2 expression was negatively associated with FOXM1 staining in a human colon carcinoma tissue microarray. Resveratrol, berberine, and quercetin reduced FOXM1 expression in colon cancer cells. Highlights Upregulation of FOXM1 may be an early molecular signal required for cancer SIRT2 and FOXM1 physically interacted, and SIRT2 deacetylated FOXM1 in vitro Strong SIRT2 expression was negatively associated with the FOXM1 staining in the TMA Resveratrol, berberine and quercetin decreased FOXM1 expression in colorectal cancer cells</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>39425454</pmid><doi>10.1002/jbt.70018</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-9467-3761</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1095-6670
ispartof Journal of biochemical and molecular toxicology, 2024-11, Vol.38 (11), p.e70018-n/a
issn 1095-6670
1099-0461
1099-0461
language eng
recordid cdi_proquest_miscellaneous_3118305886
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Acetylation
Berberine
Colon
Colon cancer
Colonic Neoplasms - genetics
Colonic Neoplasms - metabolism
Colonic Neoplasms - pathology
Colorectal cancer
Colorectal carcinoma
CRC
Deacetylation
Disease management
Female
Forkhead Box Protein M1 - genetics
Forkhead Box Protein M1 - metabolism
FOXM1
Gene Expression Regulation, Neoplastic - drug effects
HCT116 Cells
Histones
Humans
Immunomodulation
Immunoprecipitation
Inhibitors
Male
Molecular interactions
posttranslational regulation
Quercetin
Resveratrol
SirReal2
sirtuin
Sirtuin 2 - genetics
Sirtuin 2 - metabolism
Staining
Therapeutic applications
Tumor cell lines
title SIRT2 deacetylates and decreases the expression of FOXM1 in colon cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T00%3A20%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SIRT2%20deacetylates%20and%20decreases%20the%20expression%20of%20FOXM1%20in%20colon%20cancer&rft.jtitle=Journal%20of%20biochemical%20and%20molecular%20toxicology&rft.au=Yildiz,%20Baris&rft.date=2024-11&rft.volume=38&rft.issue=11&rft.spage=e70018&rft.epage=n/a&rft.pages=e70018-n/a&rft.issn=1095-6670&rft.eissn=1099-0461&rft_id=info:doi/10.1002/jbt.70018&rft_dat=%3Cproquest_cross%3E3118305886%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3126881231&rft_id=info:pmid/39425454&rfr_iscdi=true